Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE: MRK ) is no exception. Merck & Co., Inc. (NYSE:MRK)'s one of the industry's biggest giants, but the loss of patent protection on former top blockbuster drug Singulair and other leading medications has threatened this company's future. While leading drugs such as Januvia are holding up Merck & Co., Inc. (NYSE:MRK)'s foundation, the company's pipeline will make or break its long-term success. Just how strong is Merck & Co., Inc. (NYSE:MRK)'s pipeline? Let's take a look at this firm's portfolio of developmental drugs and see what investors should think of Merck & Co., Inc. (NYSE:MRK)'s potential. No shortage of drug candidates Merck & Co., Inc. (NYSE:MRK)'s pipeline isn't lacking for quantity.